Loading...
Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers.
Yap, T Krebs, Matthew G Postel-Vinay, S Bang, Y El-Khoueiry, A Abida, W Harrington, K Sundar, R Carter, Louise Castanon-Alvarez, E
Yap, T
Krebs, Matthew G
Postel-Vinay, S
Bang, Y
El-Khoueiry, A
Abida, W
Harrington, K
Sundar, R
Carter, Louise
Castanon-Alvarez, E
Citations
Altmetric:
Abstract
Description
Date
2016-12
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. 2016, 69(Suppl 1):S2 European Journal of Cancer